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The complete, 13 years, results of the Nutritional Prevention of Cancer Trial have been analysed, causing some speculation over the
robustness of the previously reported findings of reduction of cancer risks by supplements of selenium (Se) to a cohort of older
Americans. These analyses confirmed that Se supplementation was associated with marked reductions in risks to total (all-site except
skin) carcinomas and to cancers of the prostate and colon–rectum. Of those deep-site treatment effects, the most robust was for
prostate cancer, which was more frequent, and was confirmed by serum prostate-specific antigen level. Recent subgroup analyses
showed Se supplementation reduced risk of cancer mostly among subjects who entered the trial with plasma Se levels in the bottom
tertile of the cohort. Other recent findings have demonstrated that Se treatment can promote apoptosis in prostate cancer cells and,
possibly, impair their proliferation through antiangiogenic effects. Thus, a body of basic understanding is developing by which one can
understand and evaluate the results of the Nutritional Prevention of Cancer and future clinical trials. This understanding also requires
inclusion of the mechanisms of Se transport and cellular uptake, so that appropriate inferences can be made from findings from cell
culture systems, which tended to use effective Se doses much larger than relevant to cells in vivo. Also needed is information on the
chemical speciation of Se in foods, so that Se delivery can be achieved in ways that are effective in reducing cancer risk and is also safe,
accessible and sustainable.
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That selenium (Se), an essential nutrient, may have a role in
carcinogenesis was first suggested nearly 40 years ago. That
working hypothesis has subsequently developed support from the
results of a large number of animal studies that have consistently
found Se supplements to be effective in reducing experimental
carcinogenesis in virtually every tumour model investigated (see
reviews: Combs and Gray, 1998; Combs and Lu ¨, 2001). This body
of evidence not withstanding, it was a single report that stimulated
current interests in low Se status as a cancer risk factor, and in the
potential for Se-containing supplements and foods in cancer
prevention. It reported that 10 years of supplementation with a
moderate daily dose of the element could substantially reduce
cancer risks (Clark et al, 1996). Recent analyses of the complete
results of what proved to be a 13-year study have raised questions
as to the original interpretation of the earlier results and provided
the basis for other, larger chemoprevention trials using Se. It is the
purpose of this review to discuss the complete trial results in the
context of relevant recent work, particularly in research reported
in the previous year.
THE NUTRITIONAL PREVENTION OF CANCER (NPC)
TRIAL
The NPC Trial (Clark et al, 1996) was a double-blind, randomised,
placebo-controlled clinical trial designed to test the hypothesis that
a regular oral dose of Se (200mgday
 1 as Se-enriched yeast) could
reduce the rate of recurrent nonmelanoma skin cancer in a high-
risk group of 1312 older Americans living along the eastern
seaboard. The results that were first reported (Clark et al, 1996)
were for the first 10 years of the trial (15 September 1983–31
December 31 1993). They showed no significant effects of Se
treatment on the incidences of either basal or squamous cell
carcinoma of the skin. The same results, however, showed
significant treatment-associated reductions in risks to total cancer
incidence (risk ratio (RR)¼0.63), total cancer deaths (RR¼0.50)
and to the incidences of carcinomas at sites other than skin,
namely, lung (RR¼0.54), prostate (RR¼0.37), colon–rectum
(RR¼0.42) and total nonskin (RR¼0.55).
The blinding of the NPC Trial was, in fact, maintained through
31 January 1996 (about the time of publication of the original
report (Clark et al, 1996)), for a total of more than 13 calendar
years. Owing to the untimely death of the project’s lead
investigator, Dr Larry Clark, analyses of the complete trial results
were presented only recently (Duffield-Lillico et al, 2002, 2003a,b;
Reid et al, 2002). With an average of 7.9 years of follow-up per
patient, the complete results of the NPC Trial blinded phase
provide greater statistical precision than was available for the
original analysis (Clark et al, 1996) at which time only 6.4 years of
follow-up per patient had been achieved.
RECENT ANALYSES
Analyses of the complete results (Duffield-Lillico et al, 2002,
2003a,b; Reid et al, 2002) confirmed those conclusions reported
earlier in several, but not all, respects. They supported the
strongest protective effects of Se detected previously: Se treatment
was associated with reduced risks to total cancer incidence
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(RR¼0.51) and colon–rectum (RR¼0.46) (Duffield-Lillico et al,
2002). They did not, however, support the earlier finding of a
protective effect against lung cancer incidence: risk to cancer at
that site was not significantly affected by Se treatment (RR¼0.70,
P¼0.18) (Duffield-Lillico et al, 2002; Reid et al, 2002). Further,
analysis of the complete trial data seemed to require the rejection
of the previous conclusion that Se treatment did not affect the
primary end point, which was nonmelanomous skin cancer.
Duffield-Lillico et al (2003a,b) reanalysed the original (first
10 year) and complete (13 years) data, in both cases, using a
subsample of 1250 patients whose baseline blood samples had
been drawn within 4 days of the time each was randomised
to treatment. These analyses supported the original finding
(Clark et al, 1996) that, indeed, Se treatment did not affect
the risk of basal cell carcinomas (BCC). In fact, the 13-year data
also indicate that Se treatment significantly delayed the diagnosis
of the first BCC (Duffield-Lillico et al, 2003a,b). However, with the
increased statistical power of the complete data set, those analyses
also found Se treatment to be significantly associated with
increased risks to both squamous cell carcinomas (RR¼1.31,
P¼0.005) and total nonmelanomous skin cancers (RR¼1.22,
P¼0.004).
It is not clear, however, that all of these effects, regardless
of their direction, can appropriately be attributed to treatment.
This is because it can be expected that at least some cancers,
particularly those diagnosed soon after the commencement of the
trial, will have resulted from cellular events that occurred prior to
the start of the trial, perhaps years earlier. Thus, it is very
important to note that analyses of cancer outcomes diagnosed only
after 2 years of treatment showed no significant treatment effect on
SCC incidence (RR¼1.21, P40.05). Therefore, it is not clear that
Se treatment, which was clearly effective in reducing risks of
several deep-site cancers, had any effects on skin cancers.
Vinceti et al (2003) commented on the analyses of the complete
NPC Trial data by Duffield-Lillico et al (2002). As the complete
trial was only 25 months longer than the portion originally
analysed (Clark et al, 1996), Vinceti et al (2003) suggested
that relatively weaker treatment effects apparent in the former
data (Duffield-Lillico et al, 2002) must indicate that any
cancer protection by Se must occur only in the short term. While
their point may obtain to the effects on lung cancer prevalence,
they clearly do not with respect to the incidences of total
cancers nor of cancers of the prostate and colon–rectum, all of
which showed comparable responses to Se treatment in the two
periods of follow-up. Neither did Vinceti et al (2003) consider
the effects of the progressive number of patients lost to
follow-up, which, as can be expected, increased as the study
continued. Although no participants were lost to vital follow-up
(for a total of 9301 person-years), by the end of 13 year
blinded period only 36% of patients were still on treatment
(Duffield-Lillico et al, 2002). Under the ‘intention-to-treat’
paradigm of analysis, this effect could be expected to mitigate
detectable treatment effects despite the statistical gains achieved by
additional months of follow-up.
Perhaps, the most important finding from the NPC Trial was
that the cancer-protective effects of Se treatment were not
apparent for all groups of subjects. In the case of total cancer
incidence, Se treatment produced significant reductions only in
males (RR¼0.68, P¼0.008; vs RR¼1.14, P¼0.66 for females)
(Duffield-Lillico et al, 2002). This finding, however, must be
considered in the context that 75% of the trial subjects were men –
a fact resulting from the gender-blind recruitment of nonmelano-
ma skin cancer patients (predominantly male in the US) in seven
clinics, the three largest of which were in Veterans Administration
Hospitals and had predominantly male patient populations. While
that fact may have robbed the study of statistical power relative to
outcomes in women, it did the opposite for those of men.
SELENIUM AND THE PROSTATE
The most robust results of the NPC Trial come from the recent
analyses of the complete trial data for prostate cancer incidence,
the diagnosis of which was confirmed by analysis of prostate-
specific antigen (PSA) in the plasma (Duffield-Lillico et al,
2003a,b). These analyses show that, for men with PSA values
#4ngml
 1, Se treatment was associated with a 65% reduction in
prostate cancer risk (P¼0.01). In addition, after a finding of
elevated PSA, men in the Se-treated group were 40% as likely to
undergo biopsy as those in the placebo group (Po0.05). Duffield-
Lillico et al (2003a,b) suggested that this difference may indicate a
bias against the detection of prostate cancer in the Se-treated
group, but no data were presented to test that speculation. For men
entering the trial with PSA 44ngml
 1, there was no significant
effect of treatment (RR¼0.88, P¼0.86), nor did Se treatment
reduce elevated PSA values or affect the clinical stage or incidence
of advanced prostate cancers. These findings would suggest a
protective effect of Se treatment against early stage(s) of
carcinogenesis; however, there was no indication that Se treatment
affected the stage of prostatic disease among men with that
diagnosis. In contrast, Rudolph et al (2003) found that Barrett’s
oesophagus subjects with relatively high (upper three quartiles)
serum Se levels had reduced risks to developing high-grade
dysplasia.
Duffield-Lillico et al (2003a,b) also showed that the protective
effect of Se treatment against prostate cancer was significant only
for subjects who entered the trial with relatively low plasma Se
levels. Those entering with plasma Se o106.4ngml
 1
(1.35nmoll
 1), that is, in the lowest tertile of that cohort, showed
the strongest effect of Se treatment (RR¼0.14, P¼0.002) in
reducing the risk of being diagnosed with prostate cancers over the
subsequent years of follow-up. Subjects entering in the middle
tertile of plasma Se, 106.8–123.2ngml
 1 (1.37–1.58nmoll
 1),
showed a more modest, but still protective effect of Se treatment
(RR¼0.39, P¼0.03); but subjects entering in the highest tertile of
plasma Se (4123.2ngml
 1 or 41.58nmoll
 1) showed no
significant treatment effect (RR¼1.20, P¼0.66). To explore
the potential impact of a possible diagnostic bias as indicated
above, Duffield-Lillico et al (2003a,b) simulated results based
on the diagnoses they would have projected had the biopsy
rates been comparable between Se and placebo treatment
groups; despite a generally attenuated cancer incidence, their
analyses showed significant protection by Se in the lowest
plasma Se tertile group.
Other recent results support the prostate cancer-protective effect
of Se treatment indicated by the NPC Trial, which was designed
with nonmelanoma skin cancer as the primary end point. Vogt et al
(2003) conducted a case–control study of prostate cancer risk in
American whites and blacks, finding serum Se concentration to be
inversely correlated with prostate cancer incidence. Previously,
Brooks et al (2001) had shown a similar, inverse association of
prediagnostic plasma Se and prostate cancer risk, which was
seen only among men with plasma Se levels o118ngml
 1
(o1.51nmoll
 1). Van den Brandt et al (2003) found that baseline
Se status, which they assessed on the basis of toenail Se content,
was inversely related to subsequent diagnosis of prostate cancer in
a cohort of 1211 men followed for 6.3 years. Like the NPC Trial,
van den Brandt et al (2003) found the inverse relationship of Se
status and prostate cancer risk limited to former smokers, with no
significant effects in either ex-smokers or current smokers.
Further, the inverse association of Se and prostate cancer risk
appeared only among men in the three upper quintiles of baseline
toenail Se content. This finding is supported by the previous report
(Yoshizawa et al, 1998) of a strongly inverse association of toenail
Se content and prostate cancer incidence in the Health Profes-
sionals Follow-Up Study: men in the highest quintile of toenail Se
concentration (determined in 1987) having about half the risk of
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Inhibition of cell growth has been reported in a variety of cell
culture systems, but not until recently have such studies employed
prostate cancer cell lines treated with physiologically relevant
forms of the element. In studies with androgen-responsive LNCaP
cells, the inhibition of cell growth characterised by G(1) phase
arrest has been demonstrated in response to treatment with
selenomethionine (Venkateswaran et al, 2002; Bhamre et al, 2003),
a predominant form of Se in foods, or methylselenic acid (Jiang
et al, 2002), a precursor of the putative antitumorigenically active
metabolite methylselenol, which formed from the catabolism of
selenomethionine and several other food forms of Se. Methylse-
lenic acid has also been shown to cause G(1) arrest in DU145
(Gasparian et al, 2002; Wang et al, 2002) and JCA1 prostatic
carcinoma cells (Gasparian et al, 2002). In each case, Se treatment
caused caspase-mediated apoptosis, and findings of Se induction
of cyclin-dependent kinase inhibitors (Gasparian et al, 2002;
Venkateswaran et al, 2002) and downregulation of PSA transcrip-
tion (Bhamre et al, 2003; Dong et al, 2004) suggest antiproliferative
effects. Dong et al (2002) found selenomethionine treatment to be
without effect on androgen-refractory, p53-null, PC3 human
prostate cells, which effect could be restored by transfection with
the androgen receptor. This would suggest that a functioning
androgen receptor may be required for Se sensitivity; however, this
is not indicated by the recent results of Zu and Ip (2003) who
found methylselenic acid to synergise the growth-inhibitory effect
of alpha-tocopherol on PC3 cells. Methylselenic acid was also
found by Dong et al (2003) to alter the expression by PC3 cells of
genes involved in cell cycle progression. Further, selenite, which is
reductively metabolised to methylselenides, was effective in
inhibiting both primary prostatic tumours and retroperitoneal
lymph node metastases in nude mice with established orthotopic
PC3 tumors (Corcoran et al, 2004). Therefore, the emerging
picture is one of induction by Se metabolites of pathways resulting
in arrested growth and caspase-mediated programmed death of
prostatic cells, reduced androgen signaling and impaired angio-
genesis of prostatic tumors.
That Se may have a specific metabolic role in the healthy
prostate was suggested several years ago by the identification of a
15kDa selenoprotein in the rat prostatic glandular epithelium.
This protein was shown (Korotkov et al, 2001) to form a complex
with a larger protein, UDP-glucose:glycoprotein glucosyltransfer-
ase that resides in the endoplasmic reticulum and is involved in the
control of protein folding. While this finding might suggest a role
of Se in the control of protein folding, it would not appear to
explain the relatively high amounts of Se in the prostate. Arnold
and Thrasher (2003) analysed apparently normal tissue from
prostatectomy specimens from six men, finding Se concentrations
in the range of 200–267ngg
 1 (wet wt.) in five subjects and
421ngg
 1 in one subject who reported the regular use of an oral Se
supplement. Gianduzzo et al (2003) determined Se in specimens
obtained from men undergoing transurethral resection for benign
prostatic hyperplasia; they found similar prostatic Se concentra-
tions, which were modestly increased by the short-term (1 months)
use of an Se supplement (200mgday
 1) (Se treated: 241ngg
 1 vs
controls: 196ngg
 1; P¼0.016). Waters et al (2003) found similar
concentrations of Se in the canine prostate, the levels of which
were highly correlated with toenail Se (Po0.001). These findings
put the prostate in the same category with the kidney as the organs
with greatest Se contents.
IMPORTANCE OF SPECIFIC FORMS OF SELENIUM
The Se supplement used in the NPC Trial, a commercially
produced Se-enriched baker’s yeast, has not been well charac-
terised. Ip et al (2000a,b) reported that the predominant chemical
species of Se in a similar product was selenomethionine (SeMet),
accounting for more than 80% of total Se, with some 20 other
unidentified Se components. Selenomethionine appears to be a
dominant species of Se in foods, although there is no evidence that
either SeMet or another dominant food species selenocysteine
(SeCys), are directly anticarcinogenic. It appears that each must be
metabolised to have such effects.
Several Se metabolites have been shown to have anti-carcino-
genic activities in cell and/or animal model systems: selenodiglu-
tathione (GSSeSG), the reductive metabolite of the oxidised
inorganic salts (selenite, selenate), hydrogen selenide (H2Se), the
common intermediate of that reductive pathway and the
catabolism of selenoamino acids, and the methylated selenides
([CH3]xSe), which are excretory forms of the element (see review
by Combs and Lu ¨, 2001) (see Figure 1).
Hydrogen selenide appears to play a central role in Se
anticarcinogenesis by way of further metabolism. Its oxidative
metabolism produces superoxide anion (O2
 ) and hydrogen
peroxide (H2O2), which appear to induce apoptosis (Lu ¨ et al,
1995). Alternatively, its methylation produces a series of excreted
metabolites including methylselenol (CH3SeH) which appear to
arrest cells in the G1 or early S phase and induce apoptosis
(Lu ¨ et al, 1994, 1995, 1996; Zhu et al, 1996; Kaeck et al, 1997) and
to inhibit the cell cycle regulatory enzymes CDK2 and protein
kinase C (PKC) (Sinha and Medina, 1997; Sinha et al, 1999).
Ip, Ganther and co-workers (Ip and Ganther, 1990, 1991,
1992a,b; Ip et al, 1991, 2000a,b, 2002; Vadhanavikit et al, 1993;
Dong et al, 2002) demonstrated that the CH3SeH precursors
selenobetaine (CH3SeO2H) and methyl-selenocysteine (CH3SeCys)
are each more efficacious than selenite in reducing murine
mammary tumorigenesis induced by dimethylbenzanthracene.
Owing to the di- and trimethylated Se metabolites are very rapidly
excreted across the lung (dimethylselenide, [CH3]2Se) or kidney
(trimethylselenonium, [CH3]3Se
þ), they are not efficacious in such
models. Therefore, work has centered on CH3SeH precursors
(Medina et al, 2001; Ip et al, 2002). These precursors have been
found to inhibit the cell cycle regulatory proteins CDK2 and PKC
(Sinha and Medina, 1997; Sinha et al, 1999) and cyclins D1 and A,
while upregulating p27 (Ip and Dong, 2001), to arrest cells in the
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Figure 1 Intermediary metabolism of selenium. (Abbreviations of
selenoamino acids: SeMet, selenomethionine; SeCys, selenocysteine;
CH3SeH: Se-methylselenocysteine. Abbreviations of Se metabolites:
GSSeSG, selenodiglutathione; GSSeH, selenoglutathione; H2Se, hydrogen
selenide; SeO2, selenium dioxide; CH3SeH, methylselenol; CH3SeCH3,
dimethylselenide; (CH3)3Se
þ, trimethylselenonium. Abbreviations of
specific SeCys-containing proteins: GPXs, glutathione peroxidases; TDIs,
iodothyronine 50-deiodinases; TRs, thioredoxin reductases, P, selenoprotein
P; W, selenoprotein W).
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Kaeck et al, 1997; Ip et al, 2000a,b), and to inhibit the expression
of matrix metalloproteinases in vascular endothelial cells and
vascular endothelial growth factor in cancer cells (Jiang et al,
1999). From this work it appears that Se per se is not
anticarcinogenic, but instead that Se supplements and Se-rich
foods can have such protective effects to the extent that they
contain Se species that are metabolised to yield CH3SeH.
CONCLUSION
How, then, can a normal metabolic role of Se in prostate be
rationalised with the clear proapoptotic and antiproliferative
efficacy of physiologically relevant Se metabolites? The answer
would appear to concern dose. Although the serum/plasma Se
concentrations of adequately nourished humans range 70–
200ngml
 1 (0.9–2.55nmoll
 1), almost all of that Se is bound
covalently to proteins which would not be expected to be readily
available for uptake by peripheral cells such as those of the
prostate. Higher Se doses appear to be needed to produce
substantive increases in cellular uptake of Se, particularly of the
metabolites thought to be most anticarcinogenically active,
the methylselenides that are also rapidly excreted from the body.
This hypothesis still needs to be tested in cell culture systems, as it
would appear to underlie the general findings that Se is
antitumorigenic only at supranutritional doses in animal models,
and that Se supplementation can reduce cancer risks in humans
consuming nutritionally adequate amounts of the element.
It is, therefore, significant that Duffield-Lillico et al (2003a,b)
found Se supplementation to be effective in reducing pro-
state cancer risks in subjects that were nutritionally adequate,
but low ranking (lowest one or two tertiles) with respect to Se. It
should be noted that the NPC Trial used a form of Se (Se-enriched
baker’s yeast), the predominant component of which was
selenomethionine, a major food form of Se. That this form
was effective suggests that the benefits of Se in reducing cancer risk
can be achieved at levels of exposure within the normal range,
a fact that mollifies the normal safety concerns attending
supplementation/fortification efforts. The Duffield-Lillico et al
(2003a,b) findings also suggest a target blood Se level associated
with that protection, of at least 106ngml
 1 (1.35nmoll
 1) and,
perhaps, 123ngml
 1 (1.58nmoll
 1) plasma. Recent analyses of the
Third National Health and Nutrition Examination Survey (Niskar
et al, 2003) indicate that 6 and 52%, respectively, of the US male
adult population fall below those levels. As these fractions are
probably much higher in most other countries, a large number of
people would appear to be able to benefit from moderate increases
in Se intake. Delivering Se in accessible and sustainable ways will
demand a far better understanding of the chemical species of Se in
foods, with particular attention to those species capable of yielding
methylselenol metabolically.
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